UNASSIGNED: @entity3039 ( @entity3039 ) represents the epitome of acquired @entity548 diseases for the hematologist. Stemming from the interest for the safety of thrombopoietin-receptor agonists ( @entity5787 -ra) romiplostim and eltrombopag, recent data have investigated if @entity715 risk is also increased in this disorder. In @entity1 not treated with @entity5787 -ra, a slightly higher risk of @entity49 (VTE) is consistently found in @entity3039 , but not to a rate demanding special attention in the generality of cases. No significant increase of @entity715 ( @entity715 ) is apparent. However, age, splenectomy and personal risk factors may put some @entity3039 @entity1 to a particularly higher risk of venous and @entity715 (3-4 times higher than the average subject). @entity1 exposed to @entity5787 -ra present indirect evidence of a much higher risk of both @entity715 and VTE. Unfortunately, no matched control population is available and the prospective and registrative nature of these studies may have emphasized the incidence of @entity715 , which was recorded as adverse event. The clinician should be able to individualize the best treatment for the @entity1 , taking also into account the @entity715 risk, limiting active treatment of @entity3039 to those @entity1 really at risk of @entity548 . This article is protected by copyright. All rights reserved.

Is XXXX a thrombophilic disorder?

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity5787 :: ('7173', 'Gene') :: ['TPO'] @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding'] @entity49 :: ('MESH:D019851', 'Disease') :: ['venous thrombosis'] @entity3039 :: ('MESH:D016553', 'Disease') :: ['Immune thrombocytopenia', 'ITP'] @entity715 :: ('MESH:D013927', 'Disease') :: ['arterial thrombosis', 'AT', 'thrombosis', 'thrombotic']
@entity3039 :: (MESH:D016553,Disease) :: ['ITP']
